Search
  • mmahomed2

Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases

Valitor has been awarded a Phase I SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This project will continue the development of a long-acting anti-inflammatory product that is designed for intra-articular administration. Specifically, we will evaluate the efficacy of our drug to prevent post-traumatic osteoarthritis following joint injuries

18 views0 comments

Recent Posts

See All

Series A financing

Valitor is proud to announce the final close of our Series A financing, co-lead by the Berkeley Catalyst Fund and ShangPharma Innovations. This round oversubscribed our initial offering, and we raised

Valitor has recruited and hired Amy Twite, PhD

Valitor has recruited and hired Amy Twite, PhD to join our team as Director Chemistry. Amy graduated from UC Berkeley’s College of Chemistry with extensive experience in conjugation chemistry and cell

© Valitor, Inc 2021

  • LinkedIn - White Circle